The first use of Ad-vectors with CFTR gene in CF gene therapy clinical trial showed that their delivery was safe, with little or no immune response and a partial correction of Cl− transport defect (Zabner et al., 1993; Zabner et al., 1996). Here, CFTR is linked to cystic fibrosis.